Uses of mammalian cytokine; related reagents
AssigneeSchering Corporation
InventorsRENE DE WAAL MALEFYT, Liu Yong-Jun, Marehalli L. Nagalakshmi, Vassili Soumelis, Norihiko Watanabe, Wei Yuan
Life of this patent
Estimating the term…
Abstract
Provided are methods of modulating dendritic cell activity using agonists or antagonists of a mammalian cytokine. Also provided are methods of treating immune disorders.
Claims21
A method of modulating antigen presenting cell (APC) priming of a T cell comprising contacting the APC with:
- a) an agonist of TSLP/IL-50 (SEQ ID NO:1) or TSLP/IL-50 receptor (TSLP/IL-50R) (SEQ ID NOs:2, 3);
- or
- b) an antagonist of TSLP/IL-50 (SEQ ID NO:1) or TSLP/IL-50R (SEQ ID NOs:2, 3).
A method of treating a subject suffering from an immune disorder comprising treating with or administering an effective amount of:
- a) an agonist of TSLP/IL-50 (SEQ ID NO:1) or TSLP/IL-50 R (SEQ ID NOs:2, 3);
- or
- b) an antagonist of TSLP/IL-50 (SEQ ID NO:1) or TSLP/IL-50R (SEQ ID NOs:2, 3).
A method of inducing production of IL-4, IL-5, and IL-13 by a T cell comprising:
- a) contacting an APC with an agonist of TSLP/IL-50 or TSLP/IL-50 receptor;
- and
- b) priming the T cell with the APC.
A method of modulating TH2 response in a subject comprising administration of:
- a) an agonist of TSLP/IL-50 (SEQ ID NO:1) or TSLP/IL-50 receptor (TSLP/IL-50R) (SEQ ID NOs:2, 3);
- or
- b) an antagonist of TSLP/IL-50 (SEQ ID NO:1) or TSLP/IL-50R (SEQ ID NOs:2, 3).
Dependencies are inferred from the claim text.